Summary

Eligibility
for people ages 18-90 (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.

Official Title

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Details

Keywords

Amyloid Cardiomyopathy, Cardiomyopathies, Open-Label

Eligibility

Locations

  • University of California San Francisco
    San Francisco California 94143 United States
  • Stanford University
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eidos Therapeutics, a BridgeBio company
ID
NCT03536767
Phase
Phase 2 Cardiomyopathy Research Study
Study Type
Interventional
Participants
Expecting 55 study participants
Last Updated